Suggestions
Tyler Chase
MedTech Talent Acquisition & Recruitment Partnerships
Tyler Chase is a professional with a strong background in providing talent, recruitment, and growth strategies to global MedTech startups and SMEs in the Life Science industry, focusing on Medical Device (MedTech), HealthTech, Digital Health, and SaMD.
His expertise lies in Talent Acquisition, Recruitment Strategy & Execution, Business Development & Partnerships, and Management Consulting, catering to clients such as MedTech startups, growth-stage companies, SMEs, incubators, investors, and advisory boards.
As a market advisor and industry expert, Tyler offers clients access to a broad global network, industry data, and strategic organizational development solutions in the MedTech sector.
Tyler stands out for his talent acquisition and recruitment consulting practice, managing executive-level and high-volume hiring with a hands-on, accessible, and efficient approach.
With a Bachelor of Science in Molecular Biology and Microbiology, along with experience in medical research at the National Institutes of Health and two years of M.D. studies, Tyler possesses a unique skill set for the MedTech industry.
Throughout his career, Tyler has held significant roles at various organizations, including Managing Partner at MedTech Growth Partners, Analyst in Residence at HealthTech Capital, MedTech Talent & Executive Recruitment Leader at Proclinical Group, and positions at The Mullings Group.
His recruitment experience spans across all positions and functions within MedTech, from C-suite and board members to executive-level, management, and individual contributors in R&D through commercialization.
Tyler's commitment to the MedTech industry is evident through his global presence at industry conferences, where he shares his expertise in team building and hiring for medical device startups.
Highlights
Congratulations Teresa Prego on Joining EpiWatch as CEO!!
EpiWatch Inc., an AI-enabled #MedTech spin-out from Johns Hopkins focused on seizure detection and alerting for people with epilepsy (PWE), announced today that it has named industry veteran Teresa Prego as Chief Executive Officer.
Ms. Prego brings a successful track record of commercialization, market entry and operations in multiple early-stage companies. She has served in several leadership positions with global #medicaldevice companies, including Boston Scientific, Bayer and Zimmer Biomet. She brings a wealth of experience in #healthcare devices and disruptive care solutions. Her work includes both traditional medical device and direct-to-consumer healthcare products and services.
She succeeds founding CEO Dean Papadopoulos, who will remain actively involved with EpiWatch as Chief Strategist and a member of the Board of Directors.
"Dean has done a tremendous job of leading the organization through a successful clinical trial and is a key ongoing strategic asset to the organization. As we approach commercialization, it creates an excellent opportunity to grow and transition the organization. We are thrilled to have not only Teresa's passion, skill, and industry expertise but know that given her background, she will be an effective driver of the market entry of the EpiWatch portfolio of technologies," said Executive Chairman Michael Singer.
Ms. Prego's background includes substantial experience with startup and early-stage companies in the neurology and women's health market segments, as well as multiple successful exits, including MedTech Surgical's acquisition by Zimmer Biomet for the ROSA® robot. "I am excited to join EpiWatch as we focus on commercialization, and the opportunity it creates to drive improved safety and access to care for people with epilepsy," said Ms. Prego.
Among the approximately 3.5 million Americans with epilepsy, approximately 40% have seizures that are uncontrolled on current medical therapy. In addition to loss of driving privileges, social isolation, family stress, and underemployment, uncontrolled seizures can result in injuries and even death, known as Sudden Death in Epilepsy (SUDEP).
EpiWatch is developing an easy-to-deploy and patient-friendly chronic-care software platform for #epilepsy based on #AI and #machinelearning technologies. Beginning with seizure detection and alerting for tonic-clonic seizures, EpiWatch will grow to deliver a full suite of direct-to-patient care services, including seizure forecasting, screening for SUDEP (sudden unexpected death in epilepsy) risk, telehealth services, and care pathway optimization. Using commercially available smartwatches and mobile platforms, EpiWatch will keep people with epilepsy safe while enabling them, their caregivers, and their physicians to better manage their care to reduce the significant burden of the condition.
